期刊
EMBO REPORTS
卷 23, 期 3, 页码 -出版社
WILEY
DOI: 10.15252/embr.202153509
关键词
bone marrow-derived monocytes and macrophages; myeloid-derived growth factor; osteoblast; osteoclast; osteoporosis
资金
- National Natural Science Foundation of China [NSFC 81870573, 81370896, 81570730]
- National Key Research and Development Program of China [2016YFC1305601]
- Research Project of Health Commission of Hubei Province [WJ2017H0031]
This study reveals that myeloid cell-derived MYDGF plays a positive regulatory role in bone homeostasis by inhibiting bone resorption and promoting bone formation. MYDGF could be a potential novel therapeutic drug for osteoporosis, and bone marrow may be a potential therapeutic target for bone metabolic disorders.
Whether bone marrow regulates bone metabolism through endocrine and paracrine mechanism remains largely unknown. Here, we found that (i) myeloid cell-specific myeloid-derived growth factor (MYDGF) deficiency decreased bone mass and bone strength in young and aged mice; (ii) myeloid cell-specific MYDGF restoration prevented decreases in bone mass and bone strength in MYDGF knockout mice; moreover, myeloid cell-derived MYDGF improved the progress of bone defects healing, prevented ovariectomy (OVX)-induced bone loss and age-related osteoporosis; (iii) MYDGF inhibited osteoclastogenesis and promoted osteoblast differentiation in vivo and in vitro; and (iv) PKC beta-NF-kappa B and MAPK1/3-STAT3 pathways were involved in the regulation of MYDGF on bone metabolism. Thus, we concluded that myeloid cell-derived MYDGF is a positive regulator of bone homeostasis by inhibiting bone resorption and promoting bone formation. MYDGF may become a potential novel therapeutic drug for osteoporosis, and bone marrow may become a potential therapeutic target for bone metabolic disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据